ReviewStem cell research & therapy2013
HeLiVa platform: integrated heart-liver-vascular systems for drug testing in human health and disease.
Review in Stem cell research & therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- A pumpless liver-adipose model for studying metabolic dysfunction and drug responses.PloS one · 2026Article
- Vascular organs-on-chip made with patient-derived endothelial cells: technologies to transform drug discovery and disease modeling.Expert opinion on drug discovery · 2024Review
- Physiomimetic In Vitro Human Models for Viral Infection in the Liver.Seminars in liver disease · 2023Review
- Precision oncology using ex vivo technology: a step towards individualised cancer care?Expert reviews in molecular medicine · 2022Review
- From engineered heart tissue to cardiac organoid.Theranostics · 2022Review
- Latest impact of engineered human liver platforms on drug development.APL bioengineering · 2021Review
- Organ-on-chip applications in drug discovery: an end user perspective.Biochemical Society transactions · 2021Review
- Microphysiological systems: What it takes for community adoption.Experimental biology and medicine (Maywood, N.J.) · 2021Review
- Organs-on-chips: into the next decade.Nature reviews. Drug discovery · 2021Review
- Human biomimetic liver microphysiology systems in drug development and precision medicine.Nature reviews. Gastroenterology & hepatology · 2021Review
- Tissue Chips and Microphysiological Systems for Disease Modeling and Drug Testing.Micromachines · 2021Review
- Tumor-on-a-chip: from bioinspired design to biomedical application.Microsystems & nanoengineering · 2021Review
- Oncoimmunology Meets Organs-on-Chip.Frontiers in molecular biosciences · 2021Review
- Human Cell Modeling for Cardiovascular Diseases.International journal of molecular sciences · 2020Review
- Quantitative Image-Based Cell Viability (QuantICV) Assay for Microfluidic 3D Tissue Culture Applications.Micromachines · 2020Article
- Evolution of Biochip Technology: A Review from Lab-on-a-Chip to Organ-on-a-Chip.Micromachines · 2020Review
- OOCHIP: Compartmentalized Microfluidic Perfusion System with Porous Barriers for Enhanced Cell-Cell Crosstalk in Organ-on-a-Chip.Micromachines · 2020Article
- Liver regeneration and alcoholic liver disease.Annals of translational medicine · 2020Review
- Regulated differentiation of stem cells into an artificial 3D liver as a transplantable source.Clinical and molecular hepatology · 2020Review
- Multi-Organs-on-Chips: Towards Long-Term Biomedical Investigations.Molecules (Basel, Switzerland) · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Our project team is developing an integrated microphysiological platform with functionally connected vascular, liver and cardiac microtissues derived from a single line of human pluripotent stem cells. The platform enables functional representation of human physiology in conjunction with real-time biological readouts (via imaging and homologous reporters for all three cell phenotypes) and compatibility with high-throughput/high-content analysis. In this paper, we summarize progress made over the first year of the grant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.